Japan’s yanyeyi pharmaceutical company announced on the 25th that it has applied to Japan’s Ministry of health, labor and welfare for the production and sales license of covid-19 virus oral medicine. If recognized, it will be the first Japanese made covid-19 oral drug approved for marketing.
China’s domestic covid-19 oral drug breakthrough is imminent, and multiple routes are advancing simultaneously. The real biological azvudine (HIV reverse transcription inhibitor) is expected to publish the phase III clinical data of China in the near future Shanghai Junshi Biosciences Co.Ltd(688180) of vv116 (nucleosides) is currently undergoing international multicenter phase II / III clinical research and is expected to be included in the group in the middle of the year. Analysts believe that the current supply of paxlovid in the United States is insufficient due to capacity constraints. Pfizer said it would take 6-8 months to produce namatvir. For various reasons, China will not completely rely on paxlovid, and it is expected that the follow-up domestic small molecule oral drugs will follow.
According to the theme database of financial Associated Press, among the relevant listed companies:
Changjiangrunfa Health Industry Co.Ltd(002435) said on the interactive platform that the subsidiary has a good cooperative relationship with yanyeyi pharmaceutical company for many years, and the company is cooperating closely with yanyeyi Changao Pharmaceutical Technology Group Co., Ltd.
Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) subsidiary is the manufacturer of azvudine API. Uridine can be used as the raw material for the production of covid-19 oral drug monabilavir (molnupiravir: a product of MSD), and the annual production capacity of uridine of the company is about 200 tons.
